Sentences with phrase «of oncology research»

CCC's journals cover a wide range of current research serving the fields of oncology research, gene expression & therapy, pain research, cell transplantation, alternative medicine, and technology.

Rutgers Cancer Institute of New Jersey has partnered with top cancer centers across the nation to become a member of the Oncology Research Information Exchange Network (ORIEN).

This webinar will discuss the differences between these two types of lab animal diets and how they can affect different aspects of oncology research in rodents.

Prof. Richard Sullivan, director of the Institute of Cancer Policy, King's Health Partners Comprehensive Cancer Centre, King's College London, and co-author of the Annals of Oncology research paper.

Dr. Bolen, the chief scientific officer and global head of oncology research at Millennium: The Takeda Oncology Company has served in senior leadership positions at Millennium since 1999.

PDX models are created by implanting cancerous tissue from a human primary tumor directly into immunodeficient mouse or rat models, enabling acceleration of oncology research or drug discovery and development programs.

Immunotherapy has been emerging from the backdrop of oncology research for years most notably from smaller companies such as Dendreon, Kite Pharma and Juno Therapeutics as leaders in the space.

To get a sense of what that process is like, at least at one major pharmaceutical company, we turned to Bob Abraham, Pfizer's head of oncology research and development.

Not exact matches

In a statement released Tuesday, the American Society of Clinical Oncology outlined research tying alcohol to two types of cancer and told Americans to drink less.

This has also made it one of the most highly researched — approximately 50,000 oncology research papers are published annually, according to PubMed data cited by Elekta.

Participants included CEOs Jonathan Bush of Athenahealth, Ron Gutman of HealthTap, Dr. Clifford Hudis of the American Society of Clinical Oncology, Dr. Vivian Lee of University of Utah Health Care, VitalConnect CEO Nersi Nazari, James Park of Fitbit, and Andrew Witty of GSK, as well as President of Flex Health Solutions John Carlson, Multiple Myeloma Research Foundation Founder Kathy Giusti, Dr. Sanjay Gupta, Arianna Huffington, Andreessen Horowitz General Partner Vijay Pande, Parker Foundation President Sean Parker, Women's Alzheimer's Movement Founder Maria Shriver, and White House Cancer Moonshot Task Force Executive Director Greg Simon.

He also served as Global Head of the Immuno - Oncology Translational Innovation Platform where he was instrumental in rebuilding immuno - oncology (IO) research at the company, including pruning and re-orienting the discovery pOncology Translational Innovation Platform where he was instrumental in rebuilding immuno - oncology (IO) research at the company, including pruning and re-orienting the discovery poncology (IO) research at the company, including pruning and re-orienting the discovery pipeline.

While Canadian biotechnology expatriates are the focus of this initiative, FACIT continues to attract worldwide leaders in oncology research to the province, a shared mandate well established by its strategic partner, the Ontario Institute for Cancer Researchresearch to the province, a shared mandate well established by its strategic partner, the Ontario Institute for Cancer ResearchResearch (OICR).

Dr. Larry Garbo and RN Amy Zuchelkowski of New York Oncology Hematology join Medical Monday to discuss clinical research.

«Our study suggests that epigenetic changes to cells treated with cigarette smoke sensitize airway cells to genetic mutations known to cause lung cancers,» says Stephen Baylin, M.D., the Virginia and D.K. Ludwig Professor for Cancer Research and professor of oncology at the Johns Hopkins Kimmel Cancer Center.

«We're trying to build models that describe how tumors grow and respond to therapy,» said Yankeelov, director of the Center for Computational Oncology at The University of Texas at Austin (UT Austin) and director of Cancer Imaging Research in the LIVESTRONG Cancer Institutes of the Dell Medical School.

His interest in research grew while he did his medical degree at Stanford, so he enrolled in Stanford's research - residency program, which allowed him to do 2 years of traditional residency training with a 3rd - year research fellowship in hematology - oncology.

Hearing about the lipid biochemistry research from the Babraham Institute team and realising how we could translate its potential from an oncology perspective was a great moment for all of us!»

TCGA data, which has been the foundation of many immuno - oncology hypotheses and discoveries, will still be available for research.

We have estimated that up to 15 percent of patients will be candidates for dose optimization,» explained senior study author Javier F.Torres - Roca, MD, director of Clinical Research and associate member of the Department of Radiation Oncology at Moffitt.

Publishing April 4 in the Journal of Clinical Oncology, the research team compared the shortened radiation therapy schedule of about 5.5 weeks to the standard 8 - week regimen to determine if rates of cure were similar.

The guideline recommendations were developed by a multinational and multidisciplinary panel of oncology, obstetrics / gynecology, public health, cancer control, epidemiology / biostatistics, health economics, behavioral / implementation science, and patient advocacy experts, including some of the world's foremost research leaders on HPV and HPV vaccines.

The largest Phase 1 study in the history of oncology, the research was conducted at UCLA and 11 other sites in the U.S., Europe and Australia.

For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely - hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Professor Paolo Boffetta (MD), the Annals of Oncology associate editor for epidemiology and Director of the Institute of Translational Epidemiology at the Icahn School of Medicine at Mount Sinai in New York (USA), commented: «These results are extremely important in showing that reducing cancer mortality can be achieved: priority should be given to research in cancers with unfavourable trends, such as pancreatic cancer, and in reducing cancer mortality disparities, both between countries (Central / Eastern versus Western Europe), and within countries, for example, between socioeconomic groups.

«This study forms the basis for future research in patients with breast cancer and offers hope for targeted therapy for patients with aggressive triple - negative inflammatory breast cancer,» said lead researcher Mateusz Opyrchal, M.D., Ph.D., Assistant Professor of Oncology at RPCI.

The firm dropped discovery and development in the areas of diabetes, virology, and neuroscience in favor of a research focus on oncology, heart failure, genetically defined diseases, immunoscience, and fibrotic diseases.

People diagnosed with cancer gained 3.34 million years of life thanks to cancer clinical trials run by SWOG and supported with public funds, according to new study results to be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), the world's largest clinical cancer research meeting.

Researchers at the Bellvitge Biomedical Research Institute of Bellvitge, the Catalan Institute of Oncology and the University Hospital of Bellvitge have participated in an international study published in the journal Cancer Cell that describes how exosomes secreted by tumor cells contain protein and microRNA molecules capable of transform neighboring cells into tumoral cells promoting tumor growth.

Other UT Southwestern faculty members who contributed to this research are: Dr. Boning Gao, Assistant Professor with the Hamon Center for Therapeutic Oncology Research and Pharmacology; Dr. Kimmo Hatanpaa, Associate Professor of Pathology; Dr. Kemp Kernstine, Professor of Cardiovascular and Thoracic Surgery and holder of the Robert Tucker Hayes Foundation Distinguished Chair in Cardiothoracic Surgery; Dr. Yang Xie, Associate Professor of Clinical Sciences and Bioinformatics; Dr. Hong Zhu, Assistant Professor of Clinical Sciences and with the Simmons Cancer Center; Dr. Farjana Fattah, Assistant Professor with the Simmons Cancer Center and Pathology; Dr. Masaya Takahashi, Associate Professor with the Advanced Imaging Research and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal Mresearch are: Dr. Boning Gao, Assistant Professor with the Hamon Center for Therapeutic Oncology Research and Pharmacology; Dr. Kimmo Hatanpaa, Associate Professor of Pathology; Dr. Kemp Kernstine, Professor of Cardiovascular and Thoracic Surgery and holder of the Robert Tucker Hayes Foundation Distinguished Chair in Cardiothoracic Surgery; Dr. Yang Xie, Associate Professor of Clinical Sciences and Bioinformatics; Dr. Hong Zhu, Assistant Professor of Clinical Sciences and with the Simmons Cancer Center; Dr. Farjana Fattah, Assistant Professor with the Simmons Cancer Center and Pathology; Dr. Masaya Takahashi, Associate Professor with the Advanced Imaging Research and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal MResearch and Pharmacology; Dr. Kimmo Hatanpaa, Associate Professor of Pathology; Dr. Kemp Kernstine, Professor of Cardiovascular and Thoracic Surgery and holder of the Robert Tucker Hayes Foundation Distinguished Chair in Cardiothoracic Surgery; Dr. Yang Xie, Associate Professor of Clinical Sciences and Bioinformatics; Dr. Hong Zhu, Assistant Professor of Clinical Sciences and with the Simmons Cancer Center; Dr. Farjana Fattah, Assistant Professor with the Simmons Cancer Center and Pathology; Dr. Masaya Takahashi, Associate Professor with the Advanced Imaging Research and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal MResearch and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal Medicine;

The study was led by Dr. Alexandre Zlotta, Director of Uro - Oncology at Mount Sinai Hospital, and researcher with the Lunenfeld - Tanenbaum Research Institute, part of Sinai Health System in Toronto, Canada, and Dr. Paul Boutros, Principal Investigator, Informatics and Bio-computing, Ontario Institute for Cancer Research (OICR).

These include the ability to bring new, innovative products to the market; progress in oncology, such as the approval of Genentech's drug Avastin for breast cancer and advances in the use of gene therapy, despite some setbacks; continuing progress in research on stem cells; the emergence of treatments for previously untreated diseases; and solutions for food and fuel shortages, such as biocrops and biofuels.

Until now, EGFR inhibitors have only been effective at treating the 10 to 15 percent of non-small cell lung cancers that have a variant of EGFR, but the two - drug combo could potentially work for all non-small cell lung cancers, explained Dr. John Minna, Director of the Hamon Center for Therapeutic Oncology Research and Professor of Internal Medicine and Pharmacology.

A recent study by researchers from the Manchester Cancer Research Centre, published in the journal Annals of Oncology, has explored potential subtypes of DCIS and whether these subtypes relate to disease recurrence.

This research also sheds light on which patients we should watch more closely,» said lead study author Anja Mehnert, PhD, a professor of psychosocial oncology at the University of Leipzig in Germany.

«It was kind of fun being at a medical school and known as the weird guy who worked with dogs,» says Modiano, who is now a professor of comparative oncology at the University of Minnesota College of Veterinary Medicine and the Masonic Cancer Center, where his research focuses on immunology, cancer cell biology, cancer genetics, and applications of gene therapy.

The research team, led by senior author Timothy P. Cripe, MD, PhD, chief of the Division of Hematology / Oncology / BMT at Nationwide Children's Hospital, found that virotherapy doesn't always require a strong virus infection of cancer cells to cause tumors to shrink or die.

She worked with Ganz for 3 years as a junior scientist, learning about cancer and chronic disease and charting a course in the relatively new field of psycho - oncology before applying for her own research funding.

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

«This work is an example of how integrating basic science and clinical care may reveal privileged opportunities for biomedical research,» said Matthew O. Hebb, M.D., Ph.D., FRCSC, a researcher involved in the work from the Departments of Clinical Neurological Sciences (Neurosurgery), Oncology and Otolaryngology at the University of Western Ontario in Ontario, Canada.

Dr Gerrit - Jan Liefers (MD, PhD), a surgical oncologist and head of the geriatric oncology research group at Leiden University Medical Centre (Leiden, The Netherlands), said: «For a screening program to be effective, one would expect that the incidence of early stage breast cancer would increase while the incidence of advanced stage cancer would decrease because any cancer would have been detected at an earlier stage.

«We knew that ANG was involved in promoting cell growth so it was not unexpected to find that ANG stimulates proliferation of myeloid progenitor cells,» said Guo - fu Hu, PhD, Investigator in the Molecular Oncology Research Institute at Tufts Medical Center, and the paper's senior author.

The research was funded by a National Science Foundation Graduate Research Fellowship, a Mazumdar - Shaw International Oncology Fellowship, the Ruth L. Kirschstein National Research Service Award from the National Institutes of Health, the Burroughs Wellcome Fund, the National Cancer Institute, and the Howard Hughes Medical Inresearch was funded by a National Science Foundation Graduate Research Fellowship, a Mazumdar - Shaw International Oncology Fellowship, the Ruth L. Kirschstein National Research Service Award from the National Institutes of Health, the Burroughs Wellcome Fund, the National Cancer Institute, and the Howard Hughes Medical InResearch Fellowship, a Mazumdar - Shaw International Oncology Fellowship, the Ruth L. Kirschstein National Research Service Award from the National Institutes of Health, the Burroughs Wellcome Fund, the National Cancer Institute, and the Howard Hughes Medical InResearch Service Award from the National Institutes of Health, the Burroughs Wellcome Fund, the National Cancer Institute, and the Howard Hughes Medical Institute.

Alexander Anderson, Ph.D., chair of the Department of Integrated Mathematical Oncology (IMO) and Mark Robertson - Tessi, an applied research scientist in IMO, recently published a commentary on an integrative approach used to study cancer heterogeneity.

Connecting a global network of more than 40,000 cancer professionals, the society serves as the leading resource for best practices in clinical oncology research and academic and community practices.

In this case, the research team visited the oncology department of a Madrid hospital and found that low white cell levels in patients were making them susceptible to life - threatening infections.

The trials were supervised by Gerald Beattie of the Imperial Cancer Research Fund's Medical Oncology Unit in Edinburgh.

Principal investigator Leena Gandhi, MD, PhD, director of the thoracic medical oncology program at Perlmutter Cancer Center at NYU Langone Health and associate professor of Medicine in the division of Medical Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in oncology program at Perlmutter Cancer Center at NYU Langone Health and associate professor of Medicine in the division of Medical Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago.

New research presented at the American Society of Clinical Oncology (ASCO) 53rd Annual Meeting in Chicago shows that a previously untested combination of a monoclonal antibody - drug conjugate with a common chemotherapy agent has a high complete - response rate in children and young adults with relapsed or refractory Hodgkin lymphoma.

Principal investigator E. Shelley Hwang, M.D., chief of breast surgery at the Duke Cancer Institute and vice chair of research in the Duke University Department of Surgery, will lead the study through the cooperative group, The Alliance for Clinical Trials in Oncology.